摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1Z)-1-((E)-1-phenyl-3-p-tolylallylidene)thiosemicarbazide | 1334315-72-8

中文名称
——
中文别名
——
英文名称
(1Z)-1-((E)-1-phenyl-3-p-tolylallylidene)thiosemicarbazide
英文别名
(Z)-2-((E)-1-phenyl-3-p-tolylallylidene)hydrazinecarbothioamide;[(Z)-[(E)-3-(4-methylphenyl)-1-phenylprop-2-enylidene]amino]thiourea
(1Z)-1-((E)-1-phenyl-3-p-tolylallylidene)thiosemicarbazide化学式
CAS
1334315-72-8
化学式
C17H17N3S
mdl
——
分子量
295.408
InChiKey
SHPUVHYBHKPKPR-GANMIEKESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    82.5
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    对甲基苯甲醛苯乙酮溶剂黄146 、 potassium hydroxide 作用下, 以 甲醇乙醇 为溶剂, 反应 24.0h, 生成 (1Z)-1-((E)-1-phenyl-3-p-tolylallylidene)thiosemicarbazide
    参考文献:
    名称:
    Synthesis, molecular modeling and biological evaluation of chalcone thiosemicarbazide derivatives as novel anticancer agents
    摘要:
    A series of novel chalcone thiosemicarbazide derivatives (4a-4x) have been designed, synthesized, structurally determined, and their biological activities were also evaluated as potential EGFR kinase inhibitors. All the synthesized compounds are first reported. Among the compounds, compound 4r showed the most potent biological activity (IC50 = 0.78 +/- 0.05 mu M for HepG2 and IC50 = 0.35 mu M for EGFR), which is comparable to the positive controls. Docking simulation was also performed to position compound 4r into the EGER active site to determine the probable binding model. Antiproliferative assay results demonstrated that some of these compounds possessed good antiproliferative activity against HepG2. Compound 4r with potent inhibitory activity in tumor growth inhibition may be a potential anticancer agent. Crown Copyright (C) 2011 Published by Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2011.07.016
点击查看最新优质反应信息

文献信息

  • The mechanism of the reaction of hydrazines with α,β-unsaturated carbonyl compounds to afford hydrazones and 2-pyrazolines (4,5-dihydro-1H-pyrazoles): Experimental and theoretical results
    作者:Antonio de la Hoz、Ibon Alkorta、José Elguero
    DOI:10.1016/j.tet.2021.132413
    日期:2021.9
    The reaction of hydrazines with α,β-unsaturated carbonyl compounds to afford 2-pyrazolines was studied using a dissymmetric chalcone (phenyl/p-tolyl) and three hydrazines, hydrazine itself, phenylhydrazine and thiosemicarbazide. Several products were identified, and some reaction paths established thanks to the evolution of 1H and 13C NMR spectra with time. Theoretical calculations on energies and
    使用不对称查耳酮(苯基/对甲苯基)和三种肼(肼本身、苯肼和氨基硫脲)研究了肼与 α,β-不饱和羰基化合物反应生成 2-吡唑啉。由于1 H 和13 C NMR 光谱随时间的演变,确定了几种产物,并建立了一些反应路径。能量和化学位移的理论计算对于确定某些产品的结构至关重要。对于重要的步骤,计算了过渡态,而 IRC 证明需要找到一些意想不到的中间体。
  • Synthesis, molecular modeling and biological evaluation of chalcone thiosemicarbazide derivatives as novel anticancer agents
    作者:Hong-Jia Zhang、Yong Qian、Di-Di Zhu、Xu-Guang Yang、Hai-Liang Zhu
    DOI:10.1016/j.ejmech.2011.07.016
    日期:2011.9
    A series of novel chalcone thiosemicarbazide derivatives (4a-4x) have been designed, synthesized, structurally determined, and their biological activities were also evaluated as potential EGFR kinase inhibitors. All the synthesized compounds are first reported. Among the compounds, compound 4r showed the most potent biological activity (IC50 = 0.78 +/- 0.05 mu M for HepG2 and IC50 = 0.35 mu M for EGFR), which is comparable to the positive controls. Docking simulation was also performed to position compound 4r into the EGER active site to determine the probable binding model. Antiproliferative assay results demonstrated that some of these compounds possessed good antiproliferative activity against HepG2. Compound 4r with potent inhibitory activity in tumor growth inhibition may be a potential anticancer agent. Crown Copyright (C) 2011 Published by Elsevier Masson SAS. All rights reserved.
查看更多